29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
MONDAY, Aug. 25, 2025 -- Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024 respiratory virus season, according to research published in the Aug. 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ellen O. Boundy, Sc.D., from the CDC in Atlanta, and colleagues estimated infant RSV immunization coverage by summing the total number of infants who received nirsevimab and the number of women of childbearing age who received an RSV vaccine in 33 U.S. states and the District of Columbia (DC), divided by the total number of live births.
The researchers estimated that 29 percent of infants born during October 2023 to March 2024 were immunized against RSV during the 2023 to 2024 respiratory virus season across 33 states and DC, including 19 and 10 percent through infant receipt of nirsevimab and maternal RSV vaccination, respectively. By state, infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11 to 53 percent. Thirty-eight percent of infants who received nirsevimab received it within the first week of life.
"Additional efforts are needed to increase infant protection against severe RSV through maternal or infant immunization," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 -- The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published...
Infants Without Comorbidities Also at Risk for Severe RSV Infection
THURSDAY, Sept. 11, 2025 -- Comorbidities are seen less often in severe respiratory syncytial virus (RSV) infection in infants younger than 3 months compared with older children...
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
WEDNESDAY, July 30, 2025 -- Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.